Kristensen Tilde, Randers Else, Stentoft Jesper
Department of Internal Medicine, Viborg Regional Hospital, Viborg, Denmark.
Department of Hematology, University Hospital Aarhus, Aarhus, Denmark.
Leuk Res Rep. 2012 Nov 10;1(1):1-3. doi: 10.1016/j.lrr.2012.09.002. eCollection 2012.
Previously authors have recently described an association between nilotinib therapy for chronic myeloid leukemia (CML) and severe peripheral artery disease, coronary artery disease and sudden death. We present a case report of a male patient with CML who received nilotinib therapy. He developed bilateral renal artery stenosis and renovascular hypertension. He had no history of hypertension, cardiovascular disease, or diabetes, and he was a nonsmoker. Together, these observations indicated that obtaining further understanding of the effects is necessary and that extreme caution is warranted when considering second-generation tyrosine kinase inhibitors for first-line therapy in CML.
此前，有作者近期描述了尼罗替尼治疗慢性髓性白血病（CML）与严重外周动脉疾病、冠状动脉疾病及猝死之间的关联。我们报告一例接受尼罗替尼治疗的男性CML患者病例。他出现了双侧肾动脉狭窄和肾血管性高血压。他既往无高血压、心血管疾病或糖尿病史，且不吸烟。综合这些观察结果表明，有必要进一步了解其影响，并且在考虑将第二代酪氨酸激酶抑制剂用于CML一线治疗时应格外谨慎。
